HUP0200100A2 - Eljárások és készítmények a fehérvérsejtek számának fokozására - Google Patents
Eljárások és készítmények a fehérvérsejtek számának fokozásáraInfo
- Publication number
- HUP0200100A2 HUP0200100A2 HU0200100A HUP0200100A HUP0200100A2 HU P0200100 A2 HUP0200100 A2 HU P0200100A2 HU 0200100 A HU0200100 A HU 0200100A HU P0200100 A HUP0200100 A HU P0200100A HU P0200100 A2 HUP0200100 A2 HU P0200100A2
- Authority
- HU
- Hungary
- Prior art keywords
- nitrogen
- question
- general formula
- compounds
- white blood
- Prior art date
Links
- 210000000265 leukocyte Anatomy 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 238000004820 blood count Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000004122 cyclic group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000000468 ketone group Chemical group 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 229920000768 polyamine Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A találmány tárgya eljárás a fehérvérsejtek számának növelésére állatiszubjektumokban, felhasználva az (1)-es általános képletűvegyületeket. A fenti vegyületek általános képlete a következő: Z-kapocs-Z', vagy ennek gyógyszerészetileg elfogadható sója, aholZjelentése 9-32 gyűrűtagból álló ciklikus poliamin, melyek közül 3-8nitrogénatom; a szóban forgó nitrogénatomokat legalább 2 szénatomválasztja el egymástól, és ahol a szóban forgó heterociklikus részszabadon megválaszthatóan a nitrogén mellett további heteroatomottartalmazhat, és/vagy további gyűrűrendszerhez kapcsolható; ahol Z'jelentése megegyezhet a fentiekben meghatározott Z-vel, vagyalternatívaként a következő általános képlettel rendelkezhet: -N(R)-(CR2)n-X, ahol R jelentése egymástól függetlenül H vagy egyenes,elágazó vagy ciklikus alkil (1-6 szénatom) lehet, n jelentése 1 vagy2, és X jelentése aromás gyűrű, beleértve a heteroaromás gyűrűket,vagy merkaptán; ahol a ,,kapocs< kötést képvisel, így ez lehet alkilénvagy az alkilén láncban arilt, fuzionált arilt, oxigénatomokat, vagyketocsoportot, vagy nitrogén- vagy kénatomot tartalmazhat. Afentiekben jellemzett vegyületeket a WBC szám megemeléséhez hatásosmennyiségben adják be a szóban forgó szubjektumba. Ó
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11825599P | 1999-02-02 | 1999-02-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0200100A2 true HUP0200100A2 (hu) | 2002-05-29 |
| HUP0200100A3 HUP0200100A3 (en) | 2004-07-28 |
Family
ID=22377471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0200100A HUP0200100A3 (en) | 1999-02-02 | 2000-02-02 | Methods and compositions to enhance white blood cell count |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US6365583B1 (hu) |
| EP (1) | EP1148875B1 (hu) |
| JP (2) | JP4968868B2 (hu) |
| KR (1) | KR100643553B1 (hu) |
| CN (1) | CN1310642C (hu) |
| AP (1) | AP1497A (hu) |
| AT (1) | ATE268597T1 (hu) |
| AU (2) | AU772979B2 (hu) |
| BR (1) | BR0007924A (hu) |
| CA (1) | CA2361587C (hu) |
| CZ (1) | CZ20012698A3 (hu) |
| DE (1) | DE60011391T2 (hu) |
| DK (1) | DK1148875T3 (hu) |
| ES (1) | ES2222174T3 (hu) |
| HK (1) | HK1038319B (hu) |
| HU (1) | HUP0200100A3 (hu) |
| IL (1) | IL144400A (hu) |
| MX (1) | MXPA01007801A (hu) |
| NO (1) | NO20013770L (hu) |
| NZ (1) | NZ513602A (hu) |
| PT (1) | PT1148875E (hu) |
| SI (1) | SI1148875T1 (hu) |
| TR (1) | TR200102239T2 (hu) |
| WO (1) | WO2000045814A1 (hu) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506770B1 (en) * | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| US6667320B2 (en) * | 1999-12-17 | 2003-12-23 | Anormed | Chemokine receptor binding heterocyclic compounds |
| US8435939B2 (en) | 2000-09-05 | 2013-05-07 | Biokine Therapeutics Ltd. | Polypeptide anti-HIV agent containing the same |
| ATE335733T1 (de) * | 2000-09-15 | 2006-09-15 | Anormed Inc | Chemokin rezeptor bindenden heterozyklischen verbindungen |
| US6835731B2 (en) * | 2000-09-15 | 2004-12-28 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
| AU2002211393B2 (en) | 2000-09-29 | 2007-06-28 | Anormed Inc. | Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof |
| AU2002318927B2 (en) * | 2001-07-31 | 2007-01-04 | Genzyme Corporation | Methods to mobilize progenitor/stem cells |
| US7169750B2 (en) * | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
| CN101353324A (zh) | 2001-09-12 | 2009-01-28 | 阿诺麦德股份有限公司 | 对映体纯的氨基取代稠合双环的合成 |
| KR20040068339A (ko) * | 2001-12-21 | 2004-07-30 | 아노르메드 인코포레이티드 | 효능이 강화된 케모카인 수용체 결합 헤테로사이클릭 화합물 |
| US7354932B2 (en) * | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| EP1541585B1 (en) | 2002-08-27 | 2013-01-30 | Biokine Therapeutics Ltd. | Cxcr4 antagonist and use thereof |
| US7291631B2 (en) * | 2003-04-11 | 2007-11-06 | Genzyme Corporation | CXCR4 chemokine receptor binding compounds |
| US7501518B2 (en) * | 2003-04-22 | 2009-03-10 | Genzyme Corporation | Methods of making 2,6-diaryl piperidine derivatives |
| WO2004093817A2 (en) * | 2003-04-22 | 2004-11-04 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| US7498346B2 (en) * | 2003-12-11 | 2009-03-03 | Genzyme Corporation | Chemokine receptor binding compounds |
| WO2005059107A2 (en) * | 2003-12-11 | 2005-06-30 | Anormed Inc. | Chemokine receptor binding compounds |
| AU2005272653A1 (en) * | 2004-08-13 | 2006-02-23 | Anormed Inc. | Chemokine combinations to mobilize progenitor/stem cells |
| JP2008543858A (ja) * | 2005-06-15 | 2008-12-04 | ジェンザイム・コーポレーション | ケモカインレセプター結合化合物 |
| CA2619881A1 (en) * | 2005-08-16 | 2007-02-22 | Genzyme Corporation | Chemokine receptor binding compounds |
| JP2009527552A (ja) * | 2006-02-24 | 2009-07-30 | ジェンザイム・コーポレーション | 血流の増加および組織再生の促進またはそのいずれかのための方法 |
| US20100003224A1 (en) * | 2006-08-02 | 2010-01-07 | Genzyme Corporation | Combination Therapy |
| JP2010507567A (ja) * | 2006-08-07 | 2010-03-11 | ジェンザイム・コーポレーション | 併用療法 |
| WO2008075371A2 (en) * | 2006-12-21 | 2008-06-26 | Biokine Therapeutics Ltd. | T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation |
| US9155780B2 (en) | 2009-02-11 | 2015-10-13 | Yeda Research And Development Co. Ltd. | Short beta-defensin-derived peptides |
| WO2010146578A2 (en) | 2009-06-14 | 2010-12-23 | Biokine Therapeutics Ltd. | Peptide therapy for increasing platelet levels |
| EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| JP2014513727A (ja) * | 2011-05-16 | 2014-06-05 | ジェンザイム・コーポレーション | Ｃｘｃｒ４拮抗薬の使用 |
| EP2841084B1 (en) | 2012-04-24 | 2018-05-30 | Biokine Therapeutics Ltd. | Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer |
| EP3943098A3 (en) | 2015-07-16 | 2022-05-11 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
| CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
| WO2017106332A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| US10610527B2 (en) | 2015-12-22 | 2020-04-07 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
| KR102033920B1 (ko) | 2016-02-23 | 2019-10-18 | 바이오라인알엑스 리미티드 | 급성 골수성 백혈병을 치료하는 방법 |
| JP2019510785A (ja) | 2016-04-08 | 2019-04-18 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 癌を処置する方法 |
| CA3027500A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| CA3027495A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| JP7054529B2 (ja) | 2016-06-21 | 2022-04-14 | エックス４ ファーマシューティカルズ， インコーポレイテッド | Ｃｘｃｒ４阻害剤およびその使用 |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| CN109187337A (zh) * | 2018-09-10 | 2019-01-11 | 南京工业职业技术学院 | 一种筛选强韧性FeAl晶界的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US5021409A (en) * | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
| GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9400411D0 (en) | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
| US5612478A (en) | 1995-03-30 | 1997-03-18 | Johnson Matthey Plc | Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane |
| US5606053A (en) | 1995-05-02 | 1997-02-25 | Johnson Matthey Plc | Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane |
| US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| GB9511357D0 (en) | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
| JP2002529502A (ja) * | 1998-11-17 | 2002-09-10 | スミスクライン・ビーチャム・コーポレイション | 血小板減少症の治療法 |
-
2000
- 2000-02-01 US US09/495,298 patent/US6365583B1/en not_active Expired - Lifetime
- 2000-02-02 JP JP2000596934A patent/JP4968868B2/ja not_active Expired - Fee Related
- 2000-02-02 BR BR0007924-3A patent/BR0007924A/pt not_active Application Discontinuation
- 2000-02-02 AU AU25278/00A patent/AU772979B2/en not_active Ceased
- 2000-02-02 DE DE60011391T patent/DE60011391T2/de not_active Expired - Lifetime
- 2000-02-02 KR KR1020017009649A patent/KR100643553B1/ko not_active IP Right Cessation
- 2000-02-02 MX MXPA01007801A patent/MXPA01007801A/es not_active IP Right Cessation
- 2000-02-02 DK DK00903441T patent/DK1148875T3/da active
- 2000-02-02 CN CNB008033285A patent/CN1310642C/zh not_active Expired - Fee Related
- 2000-02-02 PT PT00903441T patent/PT1148875E/pt unknown
- 2000-02-02 CA CA2361587A patent/CA2361587C/en not_active Expired - Fee Related
- 2000-02-02 SI SI200030444T patent/SI1148875T1/xx unknown
- 2000-02-02 AP APAP/P/2001/002221A patent/AP1497A/en active
- 2000-02-02 IL IL144400A patent/IL144400A/en not_active IP Right Cessation
- 2000-02-02 ES ES00903441T patent/ES2222174T3/es not_active Expired - Lifetime
- 2000-02-02 WO PCT/CA2000/000104 patent/WO2000045814A1/en active IP Right Grant
- 2000-02-02 CZ CZ20012698A patent/CZ20012698A3/cs unknown
- 2000-02-02 EP EP00903441A patent/EP1148875B1/en not_active Expired - Lifetime
- 2000-02-02 AT AT00903441T patent/ATE268597T1/de not_active IP Right Cessation
- 2000-02-02 HU HU0200100A patent/HUP0200100A3/hu unknown
- 2000-02-02 TR TR2001/02239T patent/TR200102239T2/xx unknown
- 2000-02-02 NZ NZ513602A patent/NZ513602A/en unknown
-
2001
- 2001-08-01 NO NO20013770A patent/NO20013770L/no not_active Application Discontinuation
-
2002
- 2002-01-04 US US10/039,150 patent/US6670354B2/en not_active Expired - Lifetime
- 2002-01-07 HK HK02100103.2A patent/HK1038319B/zh not_active IP Right Cessation
-
2004
- 2004-08-13 AU AU2004203847A patent/AU2004203847B2/en not_active Ceased
-
2011
- 2011-02-04 JP JP2011023235A patent/JP2011088937A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0200100A2 (hu) | Eljárások és készítmények a fehérvérsejtek számának fokozására | |
| NO2020003I1 (no) | plerixafor (1,1’-[ 1,4-fenylen-bis- (metylen)]- bis1,2,8,11-tetraazacyklotetradekan) eventuelt i form av et farmasøytisk akseptabelt salt eller metallkompleks derav | |
| EA200300792A1 (ru) | Хиназолины в качестве ингибиторов ммр-13 | |
| EA200100486A1 (ru) | Производные 2-уреидотиазола, способ их получения и применение указанных веществ в качестве противоопухолевых средств | |
| EA200200299A1 (ru) | НОВЫЕ α-АМИНОКИСЛОТНЫЕ СУЛЬФОНИЛЬНЫЕ СОЕДИНЕНИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ ИХ СОДЕРЖАЩИЕ | |
| EA200601512A1 (ru) | Новые азабициклические соединения, способ их получения и фармацевтические композиции, которые их содержат | |
| SE8804688D0 (sv) | Substituerade styrenderivat | |
| DK0485219T3 (da) | Lægemidler til forebyggelse og behandling af kredsløbsorgansygdomme indeholdende spiro-3-heteroazolidinforbindelser | |
| ATE169015T1 (de) | Aminobenzoesäure derivate | |
| EA200500716A1 (ru) | Новые соединения 2,3-дигидро-4-(1h)-пиридона, способ их получения и фармацевтические композиции, которые их содержат | |
| ES2192671T3 (es) | Compuestos triciclicos que tienen actividad como inhibidores de ras-fpt. | |
| EA200001157A2 (ru) | Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции | |
| BE905297A (fr) | Derives heterocycliques. | |
| EA200200574A1 (ru) | НОВЫЕ ЦИКЛИЧЕСКИЕ α-АМИНО-γ-ГИДРОКСИАМИДНЫЕ СОЕДИНЕНИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ | |
| MY103817A (en) | Chloroaniline derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |